𝔖 Bobbio Scriptorium

✦ LIBER ✦

134: No evidence for increased transplant related toxicity in Ph+ chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL) with prior exposure to Dasatinib

✍ Scribed by M. Leiba; A. Shimoni; F. Guilhot; G. Martineau; M. Renaud; S. Francois; I. Hardan; A. Nagler

Book ID: 116279315
Publisher: Elsevier Science
Year: 2007
Tongue: English
Weight: 48 KB
Volume: 13
Category: Article
ISSN: 1083-8791
DOI: 10.1016/j.bbmt.2006.12.138

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

248: Novel tyrosine kinase inhibitor the

248: Novel tyrosine kinase inhibitor therapy (NTKI) prior to allogeneic stem cell transplantation (ASCT) in patients with chronic myeloid leukemia (CML): No evidence for increased transplant-related toxicity

✍ E. Jabbour; J. Cortes; H. Kantarjian; S. Giralt; R. Champlin; M. de Lima 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 53 KB

Prior treatment with the tyrosine kinase

Prior treatment with the tyrosine kinase inhibitors dasatinib and nilotinib allows stem cell transplantation (SCT) in a less advanced disease phase and does not increase SCT Toxicity in patients with chronic myelogenous leukemia and philadelphia positive acute lymphoblastic leukemia

✍ Shimoni, A; Leiba, M; Schleuning, M; Martineau, G; Renaud, M; Koren-Michowitz, M 📂 Article 📅 2008 🏛 Nature Publishing Group 🌐 English ⚖ 103 KB